Clinical Trial

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Name: Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC — clinical trial record (NCT07267806)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-04.

Trial Details

NCT Number	NCT07267806
Lead Sponsor	Linhui Peng
Conditions	Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
Enrollment	326 participants
Start Date	2025-10-31
Primary Completion	2029-10 (estimated)
Study Completion	2032-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-16